OBJECTIVETo evaluate the effectiveness, side effects and long term result of combination protocol of 5-fluorouracil (5-FU) and nitrocaphane (AT1258) on patients with malignant trophoblastic tumor.METHODSThe chart and follow up data of 166 patients treated from 1979 to 1988 in Liaoning Province Tumor Hospital were reviewed. 136 invasive mole and 30 choriocarcinoma were treated by a 5-FU and AT1258 combined protocol. Their immediate treatment results, side effects and long-term follow-ups were retrospectively analysed.RESULTSThe complete remission rate of invasion mole was 100.0% and choriocarcinoma 86.7%. The accumulative 5 and 10 year's survival rate for invasive mole were 100.0% and 99.3%, while 85.8% and 85.8% for choriocarcinoma. None of this group died of side effects or complication.CONCLUSION5-FU and AT1258 combination chemotherapy may be a protocol of choice in the treatment of malignant trophoblastic tumor.

01 Mar 1989·Zhonghua zhong liu za zhi [Chinese journal of oncology]

[Thermotolerant kinetics of HEp-2 cells and effect of thermotolerance on cytotoxicity of nitrocaphane].

Article

Author: Shen, G L

The thermotolerant kinetics of HEp-2 cells and its effect on cytotoxicity of Nitrocaphane (NC) were studied by colony formation assay. HEp-2 cells were exposed to two equal thermal doses (44 degrees C, 30 min) spaced at 0-24 hr intervals during which the cells were incubated at 37 degrees C. The maximum thermotolerance developed at the 8th hr and then gradually declined. Thermal dose survival curve even up to 2.5 hr of continuous exposure to 44 degrees C, no development of thermotolerance was demonstrated. If the cells were preheated at 44 degrees C for 30 min, and returned to 37 degrees C for 10 hr and then received the second heating at 44 degrees C for 3 hr, the slope of survival curve decreased (D0 = 2.26 hr). Thermotolerant ratio was 5.9. Thermosensitive HEp-2 cells were turned into thermotolerant cells by preheating at 44 degrees C, 30 min and returning to 37 degrees C for 10 hr. The thermotolerant cells showed resistance to drug or heat when they were exposed to NC or NC combined with heat.

01 Jan 1989·International Journal of HyperthermiaQ2 · MEDICINE

Enhancement of nitrocaphane cytotoxicity by hyperthermiain vitro

Q2 · MEDICINE

ArticleOA

Author: Zhang, Hong ; Li, Dingjiu ; Li, Ligeng ; Shen, Guoli

HEp-2 cells were treated with hyperthermia (39-44 degrees C) and nitrocaphane (NC) at various time intervals. A 1 h exposure to 39 degrees C and 41 degrees C was non-lethal to cells, but it did potentiate the cell killing of NC (1.0 micrograms/ml). It was further shown that the sequence between heat and the drug can affect cell survival. Cell killing effect was decreased when heat was given before or after administration of drug. In contrast the simultaneous administration of these two modalities was synergistic. Maximal thermotolerance of HEp-2 cells was developed using an 8-h interval at 37 degrees C between the cell exposures to two equal thermal doses (44 degrees C, 30 min). HEp-2 cells became thermotolerant when preheated for 30 min at 44 degrees C followed by a 10-h interval at 37 degrees C. The thermotolerant cells showed resistance to subsequent heat at 44 degrees C (D0 = 2.26 h, control D0 = 0.38 h), to subsequent NC treatment, and to heat combined with NC. However, in the thermotolerant cells, cytotoxicity of NC was still enhanced by hyperthermia.

100 Deals associated with Nitrocaphane

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ascites	CN	-	-
Bone Marrow Neoplasms	CN	-	-
Esophageal Carcinoma	CN	-	-
Lymphoma	CN	-	-
Nasopharyngeal Carcinoma	CN	-	-
Seminoma	CN	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Nitrocaphane

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation